152 related articles for article (PubMed ID: 37086483)
21. Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer.
Ge X; Behrendt CE; Yost SE; Patel N; Samoa R; Stewart D; Sedrak M; Lavasani S; Waisman J; Yuan Y; Mortimer J
Oncologist; 2023 Jul; 28(7):e488-e492. PubMed ID: 36943382
[TBL] [Abstract][Full Text] [Related]
22. The efficacy and safety of alpelisib in breast cancer: A real-world analysis.
Miller J; Armgardt E; Svoboda A
J Oncol Pharm Pract; 2022 Jul; 28(5):1152-1156. PubMed ID: 35450470
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and Pharmacodynamic of Alpelisib.
Royer B; Kaderbhaï CG; Schmitt A
Clin Pharmacokinet; 2023 Jan; 62(1):45-53. PubMed ID: 36633813
[TBL] [Abstract][Full Text] [Related]
24. Alpelisib: First Global Approval.
Markham A
Drugs; 2019 Jul; 79(11):1249-1253. PubMed ID: 31256368
[TBL] [Abstract][Full Text] [Related]
25. S.U.G.A.R: A Case to Outline Tactics for the Prevention of Alpelisib-Induced Hyperglycemia.
Thomas K; Germain M; Loch MM
J Investig Med High Impact Case Rep; 2022; 10():23247096221105249. PubMed ID: 35712858
[TBL] [Abstract][Full Text] [Related]
26. Alpelisib to treat breast cancer.
Copur MS
Drugs Today (Barc); 2020 Jun; 56(6):357-363. PubMed ID: 32525134
[TBL] [Abstract][Full Text] [Related]
27. A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer.
Lu YS; Lee KS; Chao TY; Tseng LM; Chitapanarux I; Chen SC; Liu CT; Sohn J; Kim JH; Chang YC; Yang Y; Shotelersuk K; Jung KH; Valenti R; Slader C; Gao M; Park YH
Clin Cancer Res; 2021 Jan; 27(2):408-417. PubMed ID: 32718997
[TBL] [Abstract][Full Text] [Related]
28. Alpelisib Plus Letrozole Shows Promise After CDK 4/6 Inhibitor Therapy in PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.
Oncologist; 2021 Feb; 26 Suppl 2(Suppl 2):S15-S16. PubMed ID: 33399247
[TBL] [Abstract][Full Text] [Related]
29. Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer.
Hoste G; Slembrouck L; Jongen L; Punie K; Matton T; Vander Borght S; Vanden Bempt I; Menten J; Wildiers H; Floris G; Arteaga C; Neven P
Clin Drug Investig; 2018 Nov; 38(11):1071-1075. PubMed ID: 30187361
[TBL] [Abstract][Full Text] [Related]
30. A multidisciplinary approach to optimizing care of patients treated with alpelisib.
Rugo HS; Lacouture ME; Goncalves MD; Masharani U; Aapro MS; O'Shaughnessy JA
Breast; 2022 Feb; 61():156-167. PubMed ID: 35016012
[TBL] [Abstract][Full Text] [Related]
31. Case report: Alpelisib-induced Stevens-Johnson syndrome.
Kurian CJ; Desai A; Rafferty W; Abou Hussein AK
Front Oncol; 2022; 12():954027. PubMed ID: 36249040
[TBL] [Abstract][Full Text] [Related]
32. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Juric D; Rodon J; Tabernero J; Janku F; Burris HA; Schellens JHM; Middleton MR; Berlin J; Schuler M; Gil-Martin M; Rugo HS; Seggewiss-Bernhardt R; Huang A; Bootle D; Demanse D; Blumenstein L; Coughlin C; Quadt C; Baselga J
J Clin Oncol; 2018 May; 36(13):1291-1299. PubMed ID: 29401002
[TBL] [Abstract][Full Text] [Related]
33. Acrofacial vitiligo secondary to PI3KCA inhibitor, alpelisib: case report.
Hinich MG; Hijab A
Front Oncol; 2023; 13():1255832. PubMed ID: 37965451
[TBL] [Abstract][Full Text] [Related]
34. Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment.
Raphael A; Salmon-Divon M; Epstein J; Zahavi T; Sonnenblick A; Shachar SS
Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292649
[TBL] [Abstract][Full Text] [Related]
35. Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis.
Wang S; Liu M; Lian S; Liu N; Zhang G; Zhao Q; Zhang Y; Jian L
Biomed Res Int; 2020; 2020():7451576. PubMed ID: 33376736
[TBL] [Abstract][Full Text] [Related]
36. Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer.
Cheung YM; Cromwell GE; Tolaney SM; Min L; McDonnell ME
Breast Cancer Res Treat; 2022 Apr; 192(2):303-311. PubMed ID: 35000092
[TBL] [Abstract][Full Text] [Related]
37. Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series.
Blow T; Hyde PN; Falcone JN; Neinstein A; Vasan N; Chitkara R; Hurd MA; Sardesai S; Lustberg MB; Flory JH; Volek JS; Goncalves MD
Integr Cancer Ther; 2021; 20():15347354211032283. PubMed ID: 34259084
[TBL] [Abstract][Full Text] [Related]
38. Synergistic actions of Alpelisib and Melatonin in breast cancer cell lines with PIK3CA gene mutation.
de Godoy BLV; Moschetta-Pinheiro MG; Chuffa LGA; Pondé NF; Reiter RJ; Colombo J; Zuccari DAPC
Life Sci; 2023 Jul; 324():121708. PubMed ID: 37086897
[TBL] [Abstract][Full Text] [Related]
39. BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer.
Bogani G; Chiappa V; Bini M; Ronzulli D; Indini A; Conca E; Raspagliesi F
Tumori; 2023 Apr; 109(2):244-248. PubMed ID: 35311394
[TBL] [Abstract][Full Text] [Related]
40. Case Report: Alpelisib-Induced Drug Reaction With Eosinophilia and Systemic Symptoms: A Rare Manifestation of a Common Side Effect.
Majeed U; Puiu T; Sluzevich J; Reynolds G; Acampora M; Moreno-Aspitia A; Bodiford KJ; Advani P
Front Oncol; 2021; 11():726785. PubMed ID: 34504802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
